Table 3. Reclassification of predicted risk with the addition of hepcidin in acute coronary syndrome patients.

Predicted risk (without hepcidin)	Reclassified predicted risk(with hepcidin)				% (N) of subjects reclassified
	<5%	5 to <10%	10 to <15%	≥15%	Increased risk	Decreased risk	Net correctly reclassified (%)
All-cause mortality
Dead patients (87)
<5%	18	9	7	1	42.5	11.4	31.1
5 to <10%	7	14	9	4	(37)	(10)
10 to <15%	0	2	2	5
≥15%	0	1	0	8
Survival patients (672)
<5%	451	63	8	1	16.7	7.14	-9.56
5 to <10%	33	48	16	9	(112)	(48)
10 to <15%	2	5	6	15
≥15%	0	3	5	7
NRI (95% CI)							21.5 (10.5-35.7)
							P<0.001
Cardiovascular mortality
Dead patients (66)
<5%	14	11	3	0	40.9	10.6	30.3
5 to <10%	2	10	4	2	(27)	(7)
10 to <15%	1	1	2	7
≥15%	0	0	3	6
Survival patients(693)
<5%	495	59	3	0	14.1	7.34	-6.76
5 to <10%	29	43	15	13	(98)	(51)
10 to <15%	2	5	7	9
≥15%	1	1	5	6
NRI (95% CI)							23.5 (9.51-38.4)
							P<0.001

NRI, net reclassification improvement.